From Surf Wiki (app.surf) — the open knowledge base

Innovative Medicines Initiative

European pharmaceutical research initiative

Field	Value
name	Innovative Medicines Initiative
title	Joint Technology Initiative on Innovative Medicines
keywords	Drug discovery, Drug development
funding_agency	European Commission

framework_programme	FP7
image	Logo_Innovative_Medicines_Initiative.jpg
project_type	Joint Technology Initiative (JTI)
research_objective	Re-invigorate the European bio-pharmaceutical sector and to make Europe more attractive for private research and development (R&D) investment in this sector
budget	2 billion EUR
funding	1 billion EUR
start	2008
end	2017
website

European Federation of Pharmaceutical Industries and Associations (EFPIA)

The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme.{{Cite journal | doi-access = free | doi-access = free | doi-access = free

The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks. Its €2bn budget makes it the largest biomedical public-private partnership in the world.

The funding scheme has been criticised, requiring universities to invest more money than with EU FP7 programs. Besides the non-competitive financial aspects of participation in IMI projects for academia, this criticism also discusses that intellectual property is freely flowing to industry.

The Sixth Framework Programme's research projects InnoMed AddNeuroMed and InnoMed PredTox acted as pilot projects establishing the feasibility of this particular public-private partnership. Since then, the IMI has had four funding rounds: the first call had the topic Safety, while the second call was about Efficacy. Projects for these two calls are ongoing.

The IMI 2 started in 2014 and will run until 2024, while the IMI 1 is still running. Overall budget is €3.276 billion, taken for half from the European Horizon 2020 program. Goals of that second calls are to improve clinical trials success rate, deliver clinical proof of concept, biomarkers and new medicines.

IMI-Train

In September 2014 IMI-TRAIN, an IMI/ENSO-funded education and training collaboration to support biomedical scientists and professionals, has been launched. IMI-TRAIN will serve as a collaboration platform for the currently IMI-funded education and training projects:

EMTRAIN: European Medicines Research Training Network
Eu2P: European programme in Pharmacovigilance and Pharmacoepidemiology
Pharmatrain: Pharmaceutical Medicine Training Programme
SafeSciMET: Safety Sciences Modular Education and Training

References

(2008). "Europe pledges billions to solve its drug development woes". Nature Medicine.
"Professor Michel Goldman, Innovative Medicines Initiative". research-europe.com.
(2011). "Spat over Innovative Medicines Initiative (IMI) funding and intellectual property". Nature Biotechnology.
[http://www.imi-europe.org/pilot%20project/pages/default.aspx Reference on EFPIA's IMI site] {{webarchive. link. (6 August 2008)
[http://www.imi.europa.eu/content/ongoing-projects Factsheets for IMI projects], IMI, 2011, retrieved 17 August 2011.
[http://www.emtrain.eu/index.php/news/421-imi-train-launched. IMI-Train launch announcement September 2014] (Press Release)

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

european-union-health-policy european-union-technology-policy horizon-2020-projects joint-undertakings-of-the-european-union-and-european-atomic-energy-community pharmaceutical-industry science-and-technology-in-europe

Want to explore this topic further?

Ask Mako anything about Innovative Medicines Initiative — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report